GVP Module IX, following CIOMS Working Group VIII, defines a signal as information from one or more sources that suggests a new potentially causal association, or a new aspect of a known association, between a medicine and an event, judged likely enough to justify verificatory action.
- A signal is a suggestion, not a proof. Its job is to start a check.
- A new aspect counts: a change in a known reaction's frequency, distribution (sex, age, country), duration, severity or outcome.
Signal management in the EU runs through detection, validation, (for the authorities) confirmation, analysis and prioritisation, assessment, and recommendation for action. Validation weighs:
- previous awareness: is it already in the product information, or already assessed?
- strength of the evidence: cases after removing duplicates, how many are supportive (compatible timing, a positive dechallenge or rechallenge, no other cause), consistency, dose-response, disproportionality;
- clinical relevance: seriousness, outcome and reversibility, vulnerable patients, patterns of use.
In the EU, an emerging safety issue (one that may need prompt regulatory action) is notified to the competent authorities and the Agency no later than 3 working days after the company establishes it.